European Commission Grants Approval of OGSIVEO® ( nirogacestat ) for the Treatment of Adults with Desmoid Tumors

Benzinga
2025.08.18 14:03
portai
I'm PortAI, I can summarize articles.

康涅狄格州斯坦福，2025 年 8 月 18 日（GLOBE NEWSWIRE）-- SpringWorks Therapeutics, Inc.，一家隸屬於德國達姆施塔特默克公司的醫療保健公司，今天宣佈歐洲委員會（EC）已批准 OGSIVEO®（nirogacestat）的市場授權，這是一種口服伽馬分泌酶抑制劑，

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.